ReviewTrends in endocrinology and metabolism: TEM2026
Substrate supply, compartmentation, and utilization in hepatic de novo lipogenesis.
Review in Trends in endocrinology and metabolism: TEM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hepatic de novo lipogenesis (DNL) is a fundamental process that supports energy storage, membrane biogenesis, and lipid signaling. However, chronically elevated hepatic DNL is a risk factor for insulin resistance and liver fat accumulation. If sustained, this can drive inflammation and fibrosis, with progression to cirrhosis and sometimes hepatocellular carcinoma, as well as numerous cardiometabolic comorbidities. Therefore, new discoveries on the basic mechanisms that control hepatic DNL may enable therapeutic modulation that improves major health outcomes. This review synthesizes recent advances in how the liver channels lipogenic substrates through mitochondrial and cytosolic pathways into DNL. It also highlights how these substrates regulate lipogenic flux by supplying cytosolic acetyl-CoA and NADPH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.